# A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

> **NCT03025022** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 14C-JNJ-42847922 40 mg

## Key facts

- **NCT ID:** NCT03025022
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-17
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-02-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025022, "A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03025022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*